24 completed, 9 terminated, 4 recruiting, 3 not yet recruiting. 46 Phase 2, 8 Phase 3, 4 Phase 1.
Follow Psychomotor Agitation: new trials by email Literature Review of Psychomotor Agitation trials Research Report on Psychomotor Agitation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep Ferrous Sulfate, Placebo - ADHD, Sleep Problems | Phase 1 / Phase 2 | Not yet recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 70 | 2027-03-01 | 2026-05-04 |
| Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome SRX246, Placebo - Aggressive Behavior in Fragile X Syndome | Phase 2 | Not yet recruiting | Azevan Pharmaceuticals | 80 | 2026-12-01 | 2026-10-30 |
| Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type 12 cm2 - 2 Active DMTS Patches, 6 cm2 - 1 Active and 1 Placebo DMTS Patches, Placebo - 2 Placebo DMTS Patches - Agitation | Phase 2 | Active not recruiting | Teikoku Pharma USA, Inc. | 150 | 2025-09-16 | 2026-10-27 |
| Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder BXCL501 Sublingual Film - Bipolar I Disorder, Bipolar II Disorder | Phase 2 | Completed | BioXcel Therapeutics Inc | 33 | 2025-06-19 | 2026-10-05 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease BMS-986368, Placebo - Agitation, Alzheimer Disease | Phase 2 | Recruiting | Celgene | 120 | 2025-06-09 | 2026-10-06 |
| Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease. hMSC - Alzheimer Disease, Agitation in Dementia | Phase 2 | Recruiting | Bernard (Barry) Baumel | 8 | 2025-04-29 | 2026-05-28 |
| Acute Agitation in Emergency Psychiatry Sublingual Dexmedetomidine, Buccal midazolam, Oral lorazepam - Agitation | Phase 2 / Phase 3 | Recruiting | Lone Baandrup | 132 | 2024-12-30 | 2025-01-01 |
| Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients Dexmedetomidine, Placebo - Traumatic Brain Injury, Agitation,Psychomotor | Phase 2 / Phase 3 | Not yet recruiting | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | 72 | 2024-10-01 | 2024-10-01 |
| Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care Dexmedetomidine Hydrochloride - Hyperactive Delirium, Delirium of Mixed Origin | Phase 1 / Phase 2 | Unknown | Bruyère Health Research Institute. | 50 | 2024-01-30 | 2025-04-15 |
| Life's End Benefits of cannaBidiol and tetrahYdrocannabinol T2:C100, Placebo - Agitation, Dementia | Phase 2 | Completed | University of Southern California | 120 | 2024-01-05 | 2026-09-02 |
| Dronabinol for Agitation in Dementia Crossover Trial Dronabinol - Dementia Moderate, Dementia Severe | Phase 2 | Withdrawn | Ralph H. Johnson VA Medical Center | 2023-11-01 | 2024-07-05 | |
| Nabilone for Agitation in Frontotemporal Dementia Nabilone, Placebo - Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant | Phase 2 | Terminated | Simon Ducharme, MD | 3 | 2023-03-07 | 2026-07-28 |
| Clinical Trial on Agitation in Alzheimer's Dementia IGC-AD1-Active, IGC-AD1-Placebo - Alzheimer Disease, Agitation,Psychomotor | Phase 2 | Active not recruiting | IGC Pharma, LLC | 164 | 2022-10-11 | 2026-09-30 |
| INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD INP105, Placebo - Agitation in Adolescents and Young Adults With ASD | Phase 2 | Terminated | Impel Pharmaceuticals | 8 | 2022-06-23 | 2023-09-28 |
| Intramuscular Ketamine Effect on Postnasal Surgery Agitation Ketamine Hydrochloride - Agitation, Emergence | Phase 2 | Completed | Jordanian Royal Medical Services | 193 | 2022-05-11 | 2023-01-25 |
| An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia BXCL501, Placebo film - Agitation, Dementia | Phase 2 | Terminated | BioXcel Therapeutics Inc | 5 | 2022-02-08 | 2026-08-11 |
| Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease THC-free CBD Oil, Placebo - Alzheimer Disease, Dementia | Phase 2 | Recruiting | Eastern Virginia Medical School | 40 | 2021-02-26 | 2023-02-16 |
| Study of BXCL501 In Agitation Associated With Delirium in ICU Patients BXCL501, Placebo film - Agitation, Delirium | Phase 2 | Withdrawn | BioXcel Therapeutics Inc | 2021-02-23 | 2026-08-11 | |
| Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal Dexmedetomidine, Placebo - Opioid Withdrawal | Phase 1 / Phase 2 | Completed | BioXcel Therapeutics Inc | 225 | 2020-06-09 | 2026-08-11 |
| Dexmedetomidine Sublingual Film for the Management of Agitation in Delirium: Safety and Preliminary Efficacy Dexmedetomidine sublingual film - Delirium | Phase 2 | Withdrawn | Jeff C. Huffman, MD | 2020-06-01 | 2024-05-13 |
Showing 20 of 46. Sign in to see all of them.
Alzheimer Disease (16) · Dementia (13) · Aggression (11) · Delirium (5) · Behavior (4) · Brain Injuries, Traumatic (3) · Pain (3) · Psychotic Disorders (3) · Schizophrenia (3) · Akathisia, Drug-Induced (2) · Caregiver Burden (2) · Restless Legs Syndrome (2) · Aberrant Motor Behavior in Dementia (1) · Agnosia (1)
Dyskinesias (46) · Nervous System Diseases (46) · Neurologic Manifestations (46) · Pathological Conditions, Signs and Symptoms (46) · Signs and Symptoms (46) · Neurobehavioral Manifestations (44) · Psychomotor Disorders (44) · Aberrant Motor Behavior in Dementia (43) · Behavioral Symptoms (43) · Behavior (40) · Mental Disorders (37) · Neurocognitive Disorders (28) · Central Nervous System Diseases (27) · Brain Diseases (26) · Neurodegenerative Diseases (17)
Dexmedetomidine (10) · 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine (2) · Acetaminophen (2) · Dronabinol (2) · Haloperidol (2) · Propranolol (2) · Sodium Chloride (2) · nabilone (2) · pimavanserin (2) · Bupropion (1) · Cholinergic Antagonists (1) · Clonidine (1) · Exercise (1) · Ketamine (1) · LY2812223 (1)
BioXcel Therapeutics Inc (5) · ACADIA Pharmaceuticals Inc. (2) · Johns Hopkins University (2) · Merck Sharp & Dohme LLC (2) · OPKO Health, Inc. (2) · Alexza Pharmaceuticals, Inc. (1) · Alzheimer's Disease Cooperative Study (ADCS) (1) · Assiut University (1) · Austin Health (1) · Avanir Pharmaceuticals (1) · Axsome Therapeutics, Inc. (1) · Azevan Pharmaceuticals (1) · Bernard (Barry) Baumel (1) · Brigham and Women's Hospital (1) · Bruyère Health Research Institute. (1)
United States (33) · Canada (7) · Spain (4) · United Kingdom (4) · Australia (2) · Chile (2) · China (2) · France (2) · Argentina (1) · Denmark (1) · Egypt (1) · Jordan (1) · Norway (1) · Puerto Rico (1)
BioXcel MM, MD (4) · Ali M. Abu Dalo, MD (1) · Alison E Pritchard, PhD (1) · Bernard Baumel, MD (1) · Bettina S. Husebo, MD, PhD (1) · BioXcel MM (1) · Brent Forester (1) · Brigid Reynolds, NP (1) · Clive Ballard, MD, PhD (1) · Craig Erickson, MD (1) · DP Devanand, MD (1) · Dag Aarsland, MD, Phd (1)
PMID 34532852, PMID 19454032, PMID 21294997, PMID 21765198, PMID 23013802, PMID 23257314, PMID 23611363, PMID 24806873, PMID 27247487, PMID 27524403, PMID 29136228, PMID 29859917, PMID 30732996, PMID 30753761, PMID 31182351, PMID 31322567, PMID 31547752, PMID 31672419, PMID 33660625, PMID 34059401, PMID 34629131, PMID 36280451, PMID 37296432, PMID 37732619, PMID 40562636, PMID 41350162
2016 (2), 2005 (1), 2008 (1), 2023 (1), R01AG047146 (1), R01AG050515 (1), R01AG068324 (1), R01AG095004 (1), R21DA029295 (1), U19AG010483 (1)